2 recruiting, 1 withdrawn. 3 Phase 1, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Recruiting 2, Withdrawn 1 |
| Phase 2 | 3 | Recruiting 2, Withdrawn 1 |
Follow Advanced CCNE1-amplified Solid Tumors: new trials by email Literature Review of Advanced CCNE1-amplified Solid Tumors trials Research Report on Advanced CCNE1-amplified Solid Tumors
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of ERW316 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors ERW316, Fulvestrant, Letrozole - Advanced HR+/HER2- Breast Cancer, Advanced CCNE1-amplified Solid Tumors | Phase 1 / Phase 2 | Withdrawn | Novartis Pharmaceuticals | 2026-06-30 | 2026-06-22 | |
| Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors GVV858, Fulvestrant, Letrozole - Advanced HR+/HER2- Breast Cancer, Advanced CCNE1-amplified Solid Tumors | Phase 1 / Phase 2 | Recruiting | Novartis Pharmaceuticals | 205 | 2025-12-29 | 2026-10-09 |
| Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and in Patients With Other Advanced Solid Tumors ECI830, ribociclib, fulvestrant - Advanced HR+/HER2- Breast Cancer, Advanced CCNE1-amplified Solid Tumors | Phase 1 / Phase 2 | Recruiting | Novartis Pharmaceuticals | 280 | 2025-04-03 | 2026-08-27 |
Breast Neoplasms (3) · Prostatic Neoplasms (2) · Small Cell Lung Carcinoma (1)
Breast Diseases (3) · Neoplasms (3) · Neoplasms by Site (3) · Skin Diseases (3) · Skin and Connective Tissue Diseases (3) · Genital Diseases (2) · Genital Diseases, Male (2) · Genital Neoplasms, Male (2) · Male Urogenital Diseases (2) · Prostatic Diseases (2) · Urogenital Diseases (2) · Urogenital Neoplasms (2) · Bronchial Neoplasms (1) · Carcinoma, Bronchogenic (1) · Lung Diseases (1)
Fulvestrant (3) · Letrozole (2) · ribociclib (1)
Canada (2) · Czechia (2) · Denmark (2) · France (2) · Germany (2) · Italy (2) · Japan (2) · Singapore (2) · Spain (2) · Taiwan (2) · United States (2) · Australia (1) · China (1) · Israel (1) · South Korea (1)
2025 (2)